Anti-Rheumatic Drugs - Denmark

Denmark

Denmark is expected to witness significant growth in the Anti-Rheumatic Drugs market.
By 2024, the projected revenue for this market is estimated to reach US$72.61m.
Furthermore, it is anticipated that the market will experience a steady annual growth rate of 0.50% from 2024 to 2029.
As a result, the market volume is projected to reach US$74.46m by 2029.
When compared globally, United States is expected to generate the highest revenue in the Anti-Rheumatic Drugs market, with an estimated revenue of US$34,700.00m in 2024.
Denmark has witnessed a growing demand for innovative biologic anti-rheumatic drugs, reflecting the country's commitment to advanced healthcare solutions.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Denmark has shown steady growth in recent years.

Customer preferences: Patients suffering from rheumatoid arthritis in Denmark prefer biologic drugs over traditional disease-modifying antirheumatic drugs (DMARDs) due to their higher efficacy and lower toxicity. However, the high cost of biologics has led to the government implementing strict reimbursement policies, limiting access to these drugs.

Trends in the market: The market for biologics in Denmark is expected to continue its growth trajectory due to the increasing prevalence of rheumatoid arthritis and the availability of new biologic drugs. However, the growth rate is expected to slow down due to the aforementioned reimbursement policies. Traditional DMARDs are expected to continue to hold a significant market share due to their lower cost and wider availability.

Local special circumstances: Denmark has a well-established healthcare system that provides universal access to healthcare services. The country also has a strong focus on research and development, which has led to the development of new biologic drugs for the treatment of rheumatoid arthritis.

Underlying macroeconomic factors: The Danish economy has been growing steadily in recent years, with low unemployment rates and high levels of disposable income. This has led to an increase in healthcare spending, which has benefited the Anti-Rheumatic Drugs market. However, the government's focus on cost containment has led to the implementation of strict reimbursement policies, which could limit the growth of the market in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.